Scinai Immunotherapeutics Ltd.

Equities

BVXV

US09073Q3039

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 15/07/2024 BST			5-day change	1st Jan Change
5.89 ^USD	+45.07%		+95.63%	-1.07%

07-15	Sector Update: Health Care Stocks Edge Lower Late Afternoon	MT
07-15	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as Investors Bet on a Trump Win	MT

BiondVax's Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study

January 09, 2023 at 03:01 pm

JERUSALEM - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently announced additional results in a preclinical in vivo proof-of-concept study of its innovative inhaled nanosized antibody (NanoAb) COVID-19 therapy, namely that the presence of the SARS-COV-2 virus in the lungs of hamsters treated with BiondVax's NanoAb was below detectable levels and significantly (p

Latest news about Scinai Immunotherapeutics Ltd.

Sector Update: Health Care Stocks Edge Lower Late Afternoon	07-15	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as Investors Bet on a Trump Win	07-15	MT
Top Premarket Gainers	07-15	MT
Scinai Immunotherapeutics Shares Surge as Preclinical Data for Psoriasis Therapy Show Promise	07-15	MT
Scinai Immunotherapeutics Ltd. Announces Promising Results in an In-Vivo Proof-Of-Concept Psoriatic Human Skin Model	07-15	CI
Scinai Immunotherapeutics Ltd. Provides Earnings Guidance for 2024	07-02	CI
Scinai Immunotherapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	07-02	CI
ADRs End Flat; Alarum Technologies Climbs 26%	06-27	DJ
Top Premarket Gainers	06-17	MT
Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	05-15	CI
Scinai Immunotherapeutics Plans 1-for-10 Reverse Stock Split to Avoid Possible Delisting	05-06	MT
Exchange-Traded Funds, Equity Futures Gain Slightly Pre-Bell Monday as June Rate Cut Likelihood Falls	04-08	MT
Ayana Pharma Selects Scinai Immunotherapeutics' CDMO Unit to Provide Drug Development and cGMP Manufacturing Services	04-08	CI
Scinai Immunotherapeutics Ltd. Appoints Liat Halpert as Head of Business Development and Sales	02-13	CI
Scinai Immunotherapeutics Ltd. announced that it has received $1.694259 million in funding	01-11	CI
Transcript : Scinai Immunotherapeutics Ltd. - Special Call	01-09
Scinai Immunotherapeutics Exercises Outstanding Warrants for $1.69 Million in Proceeds	12-29	MT
Scinai Immunotherapeutics Ltd. announced that it expects to receive $1.694259 million in funding	12-28	CI
Scinai Immunotherapeutics Ltd. Extends Maturity of Its Finance Facility with Scinai Immunotherapeutics from 2027 to 2031	11-29	CI
Scinai Immunotherapeutics Regains Compliance With Nasdaq's Shareholder Equity Rule	11-20	MT
Scinai Immunotherapeutics Ltd. Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting Its New CDMO Business Unit	11-06	CI
European Investment Bank Considers Extending Maturity of Scinai Immunotherapeutics Ltd. of its Financial Facility Contract	31/10/23	CI
Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	31/10/23	CI
ADRs Hold Steady, Medigus Ltd. Climbs 24.5%	09/10/23	DJ
Scinai Immunotherapeutics Ltd. announced that it has received $1.329254 million in funding	02/10/23	CI

Chart Scinai Immunotherapeutics Ltd.

Duration

Period

More charts

Company Profile

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Companyâs core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

Sector

Biotechnology & Medical Research

Calendar

11/08/2024 - Shareholders Meeting

More about the company

	1st Jan change	Capi.
SCINAI IMMUNOTHERAPEUTICS LTD.	-1.07%	2.73M
MODERNA, INC.	+22.15%	46.56B
LONZA GROUP AG	+45.60%	41.67B
IQVIA HOLDINGS INC.	-2.37%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.84%	32.4B
CELLTRION, INC.	-6.35%	28.1B
ICON PUBLIC LIMITED COMPANY	+20.42%	28.18B
UNITED THERAPEUTICS CORPORATION	+48.83%	14.52B
MEDPACE HOLDINGS, INC.	+45.00%	13.74B
BIO-TECHNE CORPORATION	+0.06%	12.17B

Other Biotechnology & Medical Research

Scinai Immunotherapeutics Ltd.

Equities

BVXV

US09073Q3039

Biotechnology & Medical Research

BiondVax's Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study

Latest news about Scinai Immunotherapeutics Ltd.

Chart Scinai Immunotherapeutics Ltd.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research